ANRONYSEPharmaceutical PreparationsFiscal year ends December 31

Alto Neuroscience, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$22.82+0.88 (+4.01%)

Close on Oct 19, 2026

Market cap: $976.99M
P/E (TTM): –
Dividend yield: –

Alto Neuroscience, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Cash & Equivalents	176	169	83	48
Cash & Short-Term Investments	176	169	83	48
Prepaid Expenses & Other	1.23	1.11	2.84	–
Other Current Assets	–	0.03	0.11	–
Total Current Assets	178	169	85	–
Property, Plant & Equipment	1.87	2.67	1.11	–
Accumulated Depreciation	-1.53	-1.00	-0.68	–
Operating Lease Right-of-Use Assets	4.26	5.04	0	–
Total Assets	185	178	87	–
Accounts Payable	1.88	1.58	1.07	–
Accrued Expenses	8.86	8.43	4.54	–
Current Portion of Long-Term Debt	0.59	0	0	–
Current Debt	0.59	0	0	–
Current Portion of Leases	1.15	0.87	0.13	–
Total Current Liabilities	11	10	5.61	–
Long-Term Debt	16	10	9.86	–
Long-Term Leases	3.82	4.52	0	–
Operating Lease Liabilities	4.97	5.39	0.13	–
Total Liabilities	34	26	17	–
Total Debt	17	10	9.86	–
Additional Paid-In Capital	353	290	5.37	–
Retained Earnings	-202	-138	-77	–
Comprehensive Income & Other	0.02	-0.10	-0.08	–
Shareholders' Equity	151	151	-72	-38
Total Equity	151	151	-72	-38
Total Liabilities & Equity	185	178	87	–
Shares Outstanding(shares)	32	27	3.83	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -41.8%

Financial strength

Current ratio: 14.85
Debt to equity: 0.07
Debt to assets: 6.4%
Cash to current liabilities: 1463.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.46
Dividend yield: –